Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 8;7:7602. doi: 10.1038/s41598-017-07632-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Verteporfin (VP) does not affect the mTOR or Akt pathway in glioblastoma cells, but increases LC3-IIB. SNB19 and LN229 cells were treated with vehicle (C), 2 µg/ml of VP (L) or 10 µg/ml of VP (H) for 24 hours protected from light at all steps. Western blots of whole cell lysates did not show an alteration in the phosphorylation status of ribosomal S6 protein (A) or of (B) p4EBP1 after VP treatment without light activation. (C) No changes in the phosphorylation levels of Akt (S473) were observed. (D) VP treatment of glioblastoma cells led to an increased expression of autophagic marker LC3-IIB in a dose-dependent manner. Cropped blots are shown. (Experiment repeated 3 times, representative blot is shown here).